Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIS phase 3 study of ravulizumab to prevent cardiac surgery-associated acute kidney injury and major adverse kidney events in patients with chronic kidney disease
CTR20232732Phase 3Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ravulizumab in acute kidney failure (AKF), major adverse kidney events (MAKE), sponsored by Alexion Pharmaceuticals. Started Dec 2023; status: terminated.
02
Drugs
ravulizumab
03
Conditions
acute kidney failure (AKF)major adverse kidney events (MAKE)
Beyond the preview
Go deeper on CTR20232732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232732.